Erythropoietin and optic neuritis in the TONE study

Affiliations

¹ Department of Clinical Neurosciences and Department of Surgery, University of Calgary, Calgary, AB T2N 2T9, Canada. Electronic address: fiona.costello@ahs.ca.

Comment

Fiona Costello. Lancet Neurol. 2021 Dec.

. 2021 Dec;20(12):970-971.

doi: 10.1016/S1474-4422(21)00378-1.

¹ Department of Clinical Neurosciences and Department of Surgery, University of Calgary, Calgary, AB T2N 2T9, Canada. Electronic address: fiona.costello@ahs.ca.

No abstract available

Conflict of interest statement

I have received speaker fees or advisory board consultant honoraria from Roche, Alexion, Accure Therapeutics, and the Sumaira Foundation.

Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.
Lagrèze WA, Küchlin S, Ihorst G, Grotejohann B, Beisse F, Volkmann M, Heinrich SP, Albrecht P, Ungewiss J, Wörner M, Hug MJ, Wolf S, Diem R; TONE study group. Lagrèze WA, et al. Lancet Neurol. 2021 Dec;20(12):991-1000. doi: 10.1016/S1474-4422(21)00322-7. Lancet Neurol. 2021. PMID: 34800417 Clinical Trial.